Jan 04, 2019 12:18 JST

Source: Eisai

Eisai's Etak Antimicrobial Spray Alpha Wins Nikkei Business Daily Awards for Superiority at the 2018 Nikkei Superior Products and Services Awards

For Dealing with Viruses and Bacteria! Antimicrobial Barrier that Lasts for 1 Week

TOKYO, Jan 04, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that it received a "Nikkei Business Daily Awards for Superiority" for its Etak Antimicrobial Spray Alpha, which contains long-acting antimicrobial agent Etak, at the 2018 Nikkei Superior Products and Services Awards sponsored by Nikkei Inc.

Since 1982, the Nikkei Superior Products and Services Awards are awarded every year to superior new products and services, and this marks the 37th iteration of the awards. Without accepting applications for nomination, award recipients are selected from among the approximately 20,000 new products and services reported in The Nikkei, The Nikkei Business Daily, The Nikkei Marketing Journal, The Nikkei Veritas, Nikkei.com (the Nikkei's electronic edition) and the Nikkei Asian Review. For screening, products and services are comprehensively assessed across six aspects:

1) Excellence in technology development
2) Cost-effectiveness
3) Contribution to business performance
4) Growth potential
5) Uniqueness
6) Commercial impact and social impact.

Etak Antimicrobial Spray Alpha was selected for offering the concept of "long-acting antimicrobial action" in the anti-virus/bacteria product market and for developing a new customer segment in consideration of ease-of-use for child-raising families due to being non-alcohol, as well as for cost-performance by providing an antimicrobial effect that lasts for one week and with 250 ml can be used for approximately 800 pushes.

Etak Antimicrobial Spray Alpha was born from a previously unheard of concept of keeping viruses and bacteria at bay with an antimicrobial barrier. The product is a spray that contains Etak, a patented long-acting antimicrobial agent developed by Professor Hiroki Nikawa of the Department of Oral Biology and Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. Not only is it possible to eliminate viruses and bacteria by simply spraying the product, the antimicrobial component is bound to the spray area, providing an antimicrobial effect that lasts for one week even after drying.

Spraying Etak Antimicrobial Spray Alpha beforehand creates an antimicrobial barrier on various objects in the surrounding environment which keeps away viruses and bacteria. Spraying coats, gloves and bags before going out will repel viruses and bacteria, and also helps prevent the spread of viruses and bacteria indoors via hands and objects. A single bottle of Etak Antimicrobial Spray Alpha can be used in a variety of lifestyle scenes including on door knobs, tables, bedding, kitchen items such as counters, chopping boards and knives, as well as in bathrooms and toilets. In addition, the product is scentless and contains no alcohol, making it also ideal for children's items such as toys, as well as nursing care items.

Together with providing Etak Antimicrobial Spray Alpha to contribute to consumers who wish to keep viruses and bacteria at bay, Eisai remains committed to ensuring the delivery of products that satisfy the diversified needs of consumers and to further increasing the benefits provided to them.

About Eisai
Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Public Relations Department
Eisai Co., Ltd. 
Source: Eisai
Sectors: BioTech

Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons
June 04 2020 10:43 JST
Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
June 02 2020 10:05 JST
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29 2020 14:54 JST
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 29 2020 10:31 JST
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
May 18 2020 12:33 JST
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting
May 14 2020 08:22 JST
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine
April 27 2020 16:26 JST
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China
April 01 2020 15:23 JST
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)
March 26 2020 16:01 JST
Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20
March 25 2020 08:38 JST
More Press release >>

Latest Press Release

More Latest Release >>